---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-088205"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:16:13.666655+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Stoke Therapeutics awards CEO Ian F. Smith $697K discretionary bonus for 2025

## Summary
- Discretionary bonus of $697,125 for CEO Ian F. Smith, equal to full target bonus for 2025.
- Smith did not participate in 2025 annual bonus program; Board determined corporate goal achievement at 150% of target.
- Bonus based on clinical and financial performance since Smith's appointment as interim CEO in March 2025 and permanent CEO in Oct 2025.

## SEC filing metadata
- accession: 0001193125-26-088205
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000119312526088205/0001193125-26-088205-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000119312526088205/d57138d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-088205
- JSON: https://secwatch.observer/filing/0001193125-26-088205.json
- Plain text: https://secwatch.observer/filing/0001193125-26-088205.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.